Last reviewed · How we verify
Gemcitabine, Vinorelbine, Eribulin, or Utidelone
Gemcitabine, Vinorelbine, Eribulin, or Utidelone is a Chemotherapy combination (nucleoside analog, vinca alkaloid, microtubule inhibitor, microtubule stabilizer) Small molecule drug developed by Sun Yat-sen University. It is currently in Phase 3 development for Non-small cell lung cancer, Breast cancer, Gastric cancer.
This is a combination of three chemotherapy agents that work through different mechanisms to inhibit cancer cell division and promote apoptosis.
This is a combination of three chemotherapy agents that work through different mechanisms to inhibit cancer cell division and promote apoptosis. Used for Non-small cell lung cancer, Breast cancer, Gastric cancer.
At a glance
| Generic name | Gemcitabine, Vinorelbine, Eribulin, or Utidelone |
|---|---|
| Sponsor | Sun Yat-sen University |
| Drug class | Chemotherapy combination (nucleoside analog, vinca alkaloid, microtubule inhibitor, microtubule stabilizer) |
| Target | Multiple: ribonucleotide reductase, microtubules, DNA synthesis |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and DNA synthesis. Vinorelbine is a semi-synthetic vinca alkaloid that disrupts microtubule formation and mitotic spindle function. Eribulin is a microtubule dynamics inhibitor that suppresses microtubule growth. Utidelone is a novel microtubule-stabilizing agent. Together, these agents target multiple pathways of cancer cell proliferation.
Approved indications
- Non-small cell lung cancer
- Breast cancer
- Gastric cancer
- Other solid tumors (phase 3 evaluation)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Peripheral neuropathy
- Fatigue
- Alopecia
Key clinical trials
- Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer (PHASE3)
- Organoid-based Functional Precision Therapy for Advanced Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gemcitabine, Vinorelbine, Eribulin, or Utidelone CI brief — competitive landscape report
- Gemcitabine, Vinorelbine, Eribulin, or Utidelone updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI
Frequently asked questions about Gemcitabine, Vinorelbine, Eribulin, or Utidelone
What is Gemcitabine, Vinorelbine, Eribulin, or Utidelone?
How does Gemcitabine, Vinorelbine, Eribulin, or Utidelone work?
What is Gemcitabine, Vinorelbine, Eribulin, or Utidelone used for?
Who makes Gemcitabine, Vinorelbine, Eribulin, or Utidelone?
What drug class is Gemcitabine, Vinorelbine, Eribulin, or Utidelone in?
What development phase is Gemcitabine, Vinorelbine, Eribulin, or Utidelone in?
What are the side effects of Gemcitabine, Vinorelbine, Eribulin, or Utidelone?
What does Gemcitabine, Vinorelbine, Eribulin, or Utidelone target?
Related
- Drug class: All Chemotherapy combination (nucleoside analog, vinca alkaloid, microtubule inhibitor, microtubule stabilizer) drugs
- Target: All drugs targeting Multiple: ribonucleotide reductase, microtubules, DNA synthesis
- Manufacturer: Sun Yat-sen University — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Non-small cell lung cancer
- Indication: Drugs for Breast cancer
- Indication: Drugs for Gastric cancer
- Compare: Gemcitabine, Vinorelbine, Eribulin, or Utidelone vs similar drugs
- Pricing: Gemcitabine, Vinorelbine, Eribulin, or Utidelone cost, discount & access